Aimovig, a migraine prevention drug, received FDA approval in September 2018. [1] It was the first in a new class of drugs called CGRP inhibitors to be approved for this indication. [2]
When is Ajovy's Patent Expiration Date?
The patent exclusivity for Ajovy (fremanezumab-vfrm) is subject to various patents, with some expiring as early as 2029. [3] DrugPatentWatch.com tracks these patent expirations and their potential impact on generic competition. [3]
What is Ajovy Used For?
Ajovy is indicated for the preventive treatment of migraine in adults. [1] It is administered via subcutaneous injection. [4]
How Does Ajovy Work?
Ajovy targets the calcitonin gene-related peptide (CGRP) pathway, which plays a role in migraine pathophysiology. By blocking CGRP, the drug is thought to reduce migraine frequency and severity. [5]
What Are the Side Effects of Ajovy?
Common side effects associated with Ajovy include injection site reactions, upper respiratory tract infections, and dizziness. [4] Serious allergic reactions have also been reported. [4]
Can Other Drugs Be Used for Migraine Prevention?
Yes, other CGRP inhibitors are available for migraine prevention, including Aimovig and Emgality. [6] Additionally, other classes of medications exist for preventive migraine treatment. [7]
Who Manufactures Ajovy?
Teva Pharmaceuticals manufactures Ajovy. [1]
---
Sources:
1. "Aimovig (erenumab-aooe) approved by U.S. Food and Drug Administration." Teva Pharmaceuticals USA, Inc., 14 Sep 2018, https://www.tevapharmaceuticals.com/news-archive/aimovig-erenumab-aooe-approved-by-u-s-food-and-drug-administration/
2. "FDA approves first treatment for migraine prevention." U.S. Food and Drug Administration, 15 Sep 2018, https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-migraine-prevention
3. "Ajovy Patent Expirations." DrugPatentWatch.com, https://drugpatentwatch.com/drug/ajovy
4. "Ajovy Prescribing Information." Teva Pharmaceuticals USA, Inc., https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210710s000lbl.pdf
5. Edelsberg, J., et al. "Calcitonin gene-related peptide (CGRP) pathway in migraine pathophysiology." Frontiers in Neurology, vol. 10, 2019, p. 756. https://www.frontiersin.org/articles/10.3389/fneur.2019.00756/full
6. "FDA approves new drug for migraine prevention." U.S. Food and Drug Administration, 27 Sep 2018, https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-migraine-prevention
7. "Migraine Headache." National Institute of Neurological Disorders and Stroke, https://www.ninds.nih.gov/health-information/disorders/migraine-headache